Europe Iron-Deficiency Anemia Therapy Market
The Europe iron-deficiency anemia therapy market is expected to reach USD 2,202.57 million by 2031 from USD 1,045.19 million in 2023, growing with a CAGR of 10.2% in the forecast period of 2024 to 2031.
Market Segmentation:
Europe Iron-Deficiency Anemia Therapy Market, By Therapy (Parenteral Iron Therapy and Oral Iron Therapy), Therapy Area (Obstetrics and Gynecology, Renal Diseases, Congestive Heart Failure (CHF), Oncology, Inflammatory Bowel Disease, and Others), Population (Adults, Geriatric, and Pediatric), End User (Hospitals, Specialty Clinics, Home Care Setting, and Others), Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacies, and Online Pharmacies), Countries (U.K., Germany, Italy, France, Spain, Belgium, Switzerland, Turkey, Russia, Netherlands, Rest of Europe) - Industry Trends and Forecast to 2031
Overview of Europe Iron-Deficiency Anemia Therapy Market Dynamics:
Driver
• Rising incidences of iron deficiency anemia
Restrain
• Stringent regulations for iron deficiency anemia therapy
Opportunity
• Increasing research and development activities
Market Players:
The key market players operating in the Europe iron-deficiency anemia therapy market are listed below:
• Vifor Pharma Ltd. (Europe)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Fresenius Kabi AG (Germany)
• PHARMACOSMOS A/S (Europe)
• Thorne (U.S.)
• Lupin (India)
• Blackmores (Australia)
• Shield Therapeutics plc (UK)
• Aspen Pharmacare Australia Pty Ltd. (Australia)
• AFT Pharmaceuticals (New Zealand)
• Alkem (India)
• Akebia Therapeutics, Inc. (U.S.)
• Farlex (India)
• GSK plc. (UK)
• Novartis AG (Switzerland)
• Orion Corporation (Europe)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Viatris Inc. (U.S.)
• Zydus (India)
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. This publisher does offer titles that are created upon receipt of order.